HAS2 and cholangiocarcinoma: The results showed that the expression of all three HAS family members (HAS1, HAS2, and HAS3) was negatively correlated with patient survival in stomach adenocarcinoma (Figure 1A), and high HAS2 expression was negatively correlated with patient survival in multiple types of solid cancers, including hepatocellular carcinoma (LIHC), lung squamous cell carcinoma (LUSC), colon adenocarcinoma (COAD), sarcoma (SARC), and cholangiocarcinoma (CHOL) (Figure 1B), suggesting that a high level of HA in tumor tissues negatively impacts the prognosis of patients with solid cancers.